Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake
Open Access
- 6 October 2016
- journal article
- research article
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 13 (1) , 1-9
Abstract
Coffee consumption is a known inducer of cytochrome P450 1A2 (CYP1A2) enzyme activity. We recently observed that a group of type-2 diabetes patients consumed more caffeine (coffee) on a daily basis than non-type-2 diabetes controls. Here, we investigated whether type-2 diabetes cases may metabolize caffeine faster than non-type-2 diabetes controls. To estimate CYP1A2 enzyme activity, an established marker of caffeine metabolism, we quantified the paraxanthine/caffeine concentration ratio in saliva in 57 type-2 diabetes and 146 non-type-2 diabetes participants in a case–control field study. All participants completed validated questionnaires regarding demographic status, health and habitual caffeine intake, and were genotyped for the functional -163C > A polymorphism of the CYP1A2 gene. In the diabetes group, we found a larger proportion of participants with the highly inducible CYP1A2 genotype. Furthermore, the paraxanthine/caffeine ratio, time-corrected to mitigate the impact of different saliva sampling times with respect to the last caffeine intake, was higher than in the control group. Participants who reported habitually consuming more caffeine than the population average showed higher CYP1A2 activity than participants with lower than average caffeine consumption. Multiple regression analyses revealed that higher caffeine intake was potentially an important mediator of higher CYP1A2 activity. Estimated CYP1A2 enzyme activity, and thus speed of caffeine metabolism, was higher in our type-2 diabetes group; this was possibly due to higher intake of caffeine, a known inducer of CYP1A2 enzyme activity. Given the fairly small sample sizes, the results need to be considered as preliminary and require validation in larger populations.Keywords
Funding Information
- Universität Zürich (Clinical Research Priority Program Sleep & Health)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_135414)
This publication has 32 references indexed in Scilit:
- Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasmaBiomedical Chromatography, 2010
- Methodological considerations for the quantification of self-reported caffeine usePsychopharmacology, 2008
- Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?Basic & Clinical Pharmacology & Toxicology, 2005
- What You See May Not Be What You Get: A Brief, Nontechnical Introduction to Overfitting in Regression-Type ModelsPsychosomatic Medicine, 2004
- Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolismBritish Journal of Clinical Pharmacology, 2003
- Heterogeneity in Assessing Self-Reports of Caffeine ExposureEpidemiology, 2002
- The paraxanthinePharmacogenetics, 1999
- Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeineBritish Journal of Clinical Pharmacology, 1999
- Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlationsPharmacogenetics, 1996
- Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in salivaPharmacogenetics, 1994